Achilles Therapeutics Company
Achilles Therapeutics is a developer of immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer. The company's immunotherapies harness the immune system to destroy cancer cells that target truncal tumor neo-antigens and flags to the immune system present on the surface of every cancer cell, enabling scientists to target and destroy tumors without harming healthy tissues.
Investors
Connections from
Founded Date:
2016-05-01
Total Funding:
212991704.0
Employee Number:
1-10
Funding Status:
IPO
Technology:
Medical BioTech
Last Funding Type:
Grant
Investors Number:
15.0
Last Funding Date:
2022-07-21
Industry:
Medical BioTech
Headquarters:
London, England, United Kingdom
Estimated Revenue:
$10M to $50M